Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Celgene???s New Crohn???s Disease Drug Impressing Analysts

October 21, 2014 – 5:00 am | Edit Post

Simulations Plus Adds To Portfolio With Release Of Membraneplus

October 21, 2014 – 5:00 am | Edit Post

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus simulation software.Mr. John DiBella, vice president for marketing and sales of Simulations Plus, said…

ResMed Inc. Enhances U-Sleep Patient Management Platform With Action View For Easier Management By Exception

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 21, 2014 /PRNewswire/ –ResMed (NYSE:RMD) today announced a significant improvement to U-Sleep, its premium patient management platform, which allows home medical equipment providers (HMEs) to quickly and effectively manage patients with sleep apnea and respiratory conditions. U-Sleep’s new Action…

Breast Implant Maker, Sientra, Inc., Sets Terms For $75 Million IPO

October 21, 2014 – 5:00 am | Edit Post

Sientra, an early-stage producer of silicone gel breast implants, announced terms for its IPO on Monday. The Santa Barbara, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Sientra would command a fully diluted market value of $230 million.BusinessSientra received FDA approval in 2012 for…

Allergan Inc. Chops Jobs In Carlsbad

October 21, 2014 – 5:00 am | Edit Post

ISI Group: AbbVie???s Dividend, Repurchasing Attempt Could Mean More Debt

October 21, 2014 – 5:00 am | Edit Post

Ivantis, Inc. Announces HYDRUS II Glaucoma Study Met Primary Endpoint In A Randomized Controlled Trial At Two Years

October 21, 2014 – 5:00 am | Edit Post

IRVINE, Calif.–(BUSINESS WIRE)–Ivantis, Inc., developer of the novel Hydrus Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today announced that the international HYDRUS II trial met its primary endpoint by a wide margin. Results of the randomized, controlled study showed that the Hydrus Microstent, a minimally invasive glaucoma surgery…

Aptose Biosciences Announces Approval For Listing On The Capital Market Shares To Begin Trading Under The Symbol APTO

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 21, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, announced today that its common shares…

Neurocrine Biosciences, Inc. Announces Initiation Of Phase 3 Study For VMAT2 Inhibitor NBI-98854

October 21, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Monoamine Transporter 2 compound, NBI-98854. The design of the Kinect 3 Study is a randomized, parallel-group, double…

Contract Research Organization Announces Clinical Trial Patient Rescue Program With A Pay-Per-Patient Enrolled Pricing Structure

October 21, 2014 – 5:00 am | Edit Post

COSTA MESA, Calif., Oct. 21, 2014 /PRNewswire-iReach/ — WCCT Global, a full service contract research organization headquartered in Southern California announced today the launch of a clinical trial patient recruitment…